Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The precise incidence of bullous pemphigoid in children and other bullous dermatoses in childhood are unknown. 4, 7, 13 The first case of juvenile BP confirmed by immunofluorescence was published in ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

The FDA has approved Sanofi and Regeneron’s Dupixent as a treatment for adults with bullous pemphigoid, a rare chronic autoimmune skin condition that causes severe itching, painful blisters and open ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

We have used immunofluorescence imaging to study binding of a monoclonal antibody fragment to subcutaneously implanted human melanoma cells in nude mice. The data acquired using this nontraditional ...

Bullous pemphigoid is a rare and severe adverse reaction to immune-checkpoint inhibitors that can be life-threatening. Here, we present two cases of bullous pemphigoid secondary to nivolumab and ...

A man in his 70s with a history of unresectable hepatocellular carcinoma (HCC) treated with nivolumab presented with a blistering rash 14 months after nivolumab initiation. Biopsies and direct ...